Intel stock spikes after report of possible US government stake
Ryan Fukushima, Chief Operating Officer of Tempus AI , Inc. (NASDAQ:TEM), recently executed a series of stock sales totaling $494,307, according to a recent SEC filing. The transactions, dated May 20, 2025, involved the sale of 7,820 shares of Class A Common Stock at prices ranging from $63.21 to $63.70 per share. The stock, currently trading at $59.25, has shown strong momentum with a 75.5% gain year-to-date, though InvestingPro analysis indicates the stock is trading above its Fair Value.
These sales were conducted to satisfy statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by Tempus AI’s equity incentive plans. Following these transactions, Fukushima retains direct ownership of 876,640 shares. Additionally, he holds indirect ownership of 131,893 shares through the Ryan Fukushima Irrevocable Family Trust and 150,000 shares through his spouse. With a market capitalization of $10.06 billion and trading at a high Price/Book multiple of 31.4x, investors can access detailed valuation metrics and 6 additional key insights through InvestingPro’s comprehensive research reports.
In other recent news, Tempus AI Inc. reported a significant increase in its first-quarter 2025 earnings, with revenue surging 75.4% year-over-year to $255.7 million, surpassing the forecast of $248.5 million. The company also reported an earnings per share (EPS) of -$0.24, slightly better than the anticipated -$0.26. In a strategic move, Tempus AI announced a multi-year collaboration with Boehringer Ingelheim to enhance cancer treatment research using AI and real-world data. Additionally, Tempus AI partnered with Verastem (NASDAQ:VSTM) Oncology to develop a companion diagnostic test for ovarian cancer, building on the success of Verastem’s clinical trial.
Morgan Stanley (NYSE:MS) has increased its price target for Tempus AI to $65 from $60, maintaining an Overweight rating, following the company’s strong first-quarter performance. The firm highlighted Tempus AI’s development contract with AstraZeneca (NASDAQ:AZN) and the Pathos foundation, which brings the total contract value to over $1 billion. This expanded partnership is expected to drive medium-term growth in Tempus AI’s Data and Services business. The company’s collaboration with AstraZeneca and Pathos is anticipated to contribute approximately $25-30 million in the second half of 2025.
Tempus AI’s ongoing partnership with Boehringer Ingelheim aims to integrate Tempus’s database and analytical platform with Boehringer Ingelheim’s oncology pipeline. This collaboration is expected to accelerate drug discovery processes. Meanwhile, Tempus AI’s collaboration with Verastem Oncology focuses on developing a diagnostic test for recurrent low-grade serous ovarian cancer, leveraging Tempus’s xT CDx assay. These collaborations and strategic developments underscore Tempus AI’s commitment to advancing precision medicine and improving patient outcomes in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.